antiangiogenic paptide vaccine

Developed for: hepatocellular carcinoma
Investigated by: Fukushima Medical University · Human Genome Center, Institute of Medical Science, University of Tokyo

today NCT01266707 · Ph 1

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01266707	Mar 2007 → Mar 2012	hepatocellular carcinoma	Fukushima Medical University	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	antiangiogenic paptide vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01266707 ↗
Modality	Peptide	“peptide vaccine” NCT01266707 ↗